Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Fatih Demirkan
Dokuz Eylül University
Publications 118
Published on Jul 1, 2019in Pharmaceutical Research 3.90
Silvia Maria Lavezzi1
Estimated H-index: 1
Silvia Maria Lavezzi (UNIPV: University of Pavia)+ 16 AuthorsJavier Loscertales15
Estimated H-index: 15
Introduction In the HELIOS trial, bendamustine/rituximab (BR) plus ibrutinib (BR-I) improved disease outcomes versus BR plus placebo in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Here, we describe the pharmacokinetic (PK) observations, along with modeling to further explore the interaction between ibrutinib and rituximab.
Published on Apr 1, 2019in Transfusion and Apheresis Science 1.41
Serdal Korkmaz5
Estimated H-index: 5
(UHSA: University of Health Sciences Antigua),
Serdal Korkmaz2
Estimated H-index: 2
(UHSA: University of Health Sciences Antigua)
+ 46 AuthorsDeniz Goren Sahin1
Estimated H-index: 1
(Istanbul Bilim University)
Abstract Therapeutic plasma exchange (TPE) is used to treat more than 60 diseases worldwide and has drawn growing interest. Little is known about the current situation of TPE activity in Turkey, so we developed a survey to obtain information about this timely topic. We collected data on TPE from 28 apheresis units throughout Turkey. We performed a total of 24,912 TPE procedures with 3203 patients over the past decade. Twenty years ago, the majority of procedures were performed for neurological a...
Published on May 24, 2019in Turkish Journal of Hematology 0.78
Rafiye Çiftçiler1
Estimated H-index: 1
Ömür Gökmen Sevindik3
Estimated H-index: 3
+ 10 AuthorsMehmet Hilmi Dogu3
Estimated H-index: 3
Published on Apr 1, 2019in Leukemia 9.94
Graeme Fraser16
Estimated H-index: 16
(McMaster University),
Paula Cramer17
Estimated H-index: 17
(University of Cologne)
+ 25 AuthorsMarie-Sarah Dilhuydy15
Estimated H-index: 15
We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without deletion 17p. Overall, 578 patients were randomized 1:1 to either ibrutinib (420 mg daily) or placebo, in combination with 6 cycles of BR, followed by ibrutinib or placebo alone. Median follow-up was 34.8 months (range: 0.1–45.8). Investigator-assessed median progre...
Published on Feb 1, 2019in The Lancet Haematology 11.99
Anas Younes70
Estimated H-index: 70
(MSK: Memorial Sloan Kettering Cancer Center),
Nina Bhardwaj77
Estimated H-index: 77
(ISMMS: Icahn School of Medicine at Mount Sinai)
+ 28 AuthorsFrancesc Bosch51
Estimated H-index: 51
Summary Background Preclinical studies have shown synergistic antitumour effects between ibrutinib and immune-checkpoint blockade. The aim of this study was to assess the safety and activity of ibrutinib in combination with nivolumab in patients with relapsed or refractory B-cell malignant diseases. Methods We did a two-part, open-label, phase 1/2a study at 21 hospitals in Australia, Israel, Poland, Spain, Turkey, and the USA. The primary objective of part A (dose escalation) was to assess the s...
Published on Jan 1, 2019in Lancet Oncology 35.39
Carol Moreno24
Estimated H-index: 24
(Autonomous University of Barcelona),
Richard Greil56
Estimated H-index: 56
+ 17 AuthorsDina Ben-Yehuda34
Estimated H-index: 34
(HUJI: Hebrew University of Jerusalem)
Summary Background Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard first-line treatments in chronic lymphocytic leukaemia. We compared the efficacy of the combination of ibrutinib plus obinutuzumab with chlorambucil plus obinutuzumab in first-line chronic lymphocytic leukaemia or small lymphocytic lymphoma. Methods iLLUMINATE is a multicentre, randomised, open-label, phase 3 trial done at 74 academic and com...
Published on Jan 1, 2019
Pinar Tosun Tasar3
Estimated H-index: 3
Ömer Karaşahin1
Estimated H-index: 1
+ 3 AuthorsFatih Demirkan11
Estimated H-index: 11